- Suppresses spasms of the digestive system.
- The effectiveness of Buscopan was also supported by the overall improvement in the behavioral attitudes of the horses.
Buscopan is indicated for the control of abdominal pain colic associated with spasmodic colic, flatulent colic, and simple impactions in horses.
Buscopan should not be used in impaction colics associated with ileus, or in horses with glaucoma.
Do not use in horses intended for human consumption. Not for use in humans. Keep out of reach of children. If ingested, contact a physician immediately.
Buscopan is not recommended for use in nursing foals or in pregnant or lactating mares, as safety has not been established. The effects of Buscopan may be potentiated by the concomitant use of other anticholinergic drugs. Studies of concomitant administration of Buscopan with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring adjunctive therapy. The safety of Buscopan has not been established for intramuscular IM administration. Administration of Buscopan results in heart rate elevation. Heart rate can not be used as a valid indicator of severity of pain for 30 minutes following IV injection.
Transient tachycardia and decreased borborygmal sounds lasted approximately 30 minutes following administration. Transient pupillary dilation may also be observed.
Manufactured for: Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506 Buscopan is a registered trademark of Boehringer Ingelheim Pharma GmbH & Co. KG and used under license.
Dosage and Administration:
Administer a single injection of 0.3 mg/kg body weight 0.14 mg/lb, slowly IV.
This is equivalent to 30 mg N-butylscopolammonium bromide per 100 kg 220 pounds body weight or 1.5 mL of Buscopan Injectable Solution per 100 kg 220 pounds body weight.
It is important to follow your Veterinarian's prescription instructions for your pet.
N-butylscopolammonium bromide, 20 mg/mL